Figure 7. Monitoring the presence of infused MART-1-specific, TCR-engineered T cells.
(A) Flow cytometry plots (top panels) and NACS (bottom panels) monitoring the transduction of T cells with a MART-1-specific TCR. (B) Blood cells from patient F5-1 were collected at days 0, 9, 14 and 30 after infusion. The abundance of MART-1-specific T cells was monitored by NACS (left axis) and flow cytometry (right axis).